EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$43.07
+2.67%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.55
- Revenue estimate
- $129.2M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.53
- EPS estimate
- -$0.47
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -4.1%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $51
- PT range
- $36 – $60
- Analysts
- 7
6 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026